Cerebrolysin
Independent reviews find little clear benefit after stroke.
Not a single peptide but a purified extract of pig brain, given by infusion. It is widely used for stroke and dementia in Russia, Eastern Europe and China. Independent reviews are much less positive than its reputation there. Made by EVER Neuro Pharma, also called Pig-brain peptide extract.
What the evidence shows
Side effects and risks
Who should avoid it: Self-injection. It is a hospital infusion.
How it works
- Where it acts
- A mixture of brain-derived peptides said to act like nerve growth factors.
- What it changes
- In lab and animal studies, protection and repair of nerve cells.
- What people notice
- Given by drip over weeks. Independent reviews find little clear benefit after stroke. Dizziness and headache occur.
How it is given
Into a vein in a clinic. Stroke trials used 30 mL a day for 10 days. Products sold to swallow are broken down in the gut.
Getting it in the United States
The legal route for Cerebrolysin
Not FDA-approved and not eligible for pharmacy compounding. Vials sold for research use only are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Unapproved imports and oral products
It has no US approval for any condition. A charity review notes oral versions are sold but peptides are likely broken down in the gut, and that animal-derived injections carry contamination risk.
Source: ADDF Cognitive Vitality report on Cerebrolysin, 2016-09
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Clearer thinking during a course
Reported problems
- Agitation and poor sleep
- A course means daily infusions or injections
- Cost
What experts and influencers say
Recorded views, not a survey or scientific consensus. Cautions may concern misuse or unapproved products. Statements are paraphrased; check each source for context.
Supportive expert view
Argued that Cerebrolysin should be treated as an evidence-based therapy for routine use in acute and subacute stroke care, pointing to its inclusion in Austrian, German, Canadian and European neurology society guidance.
Michael BraininWebsiteRecommends
Money: Interview was published on the manufacturer's website
Photo source: world-stroke.org
Cautionary expert view
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
See all views 7
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
Argued that Cerebrolysin should be treated as an evidence-based therapy for routine use in acute and subacute stroke care, pointing to its inclusion in Austrian, German, Canadian and European neurology society guidance.
Michael BraininWebsiteRecommends
Money: Interview was published on the manufacturer's website
Photo source: world-stroke.org
Its evidence report says meta-analyses suggest modest benefit in mild to moderate Alzheimer's disease that larger well-controlled trials have not confirmed. It notes the drug has no US approval.
Source: ADDF Cognitive Vitality report on Cerebrolysin, 2016-09
Led the 2023 Cochrane stroke review. Said the drug is widely used in Russia, former Soviet states, Eastern Europe and China, found no benefit, and said her team would not recommend routine use in acute ischemic stroke.
Source: Cochrane podcast, 2023
Liliya ZiganshinaSourceWarns against
Co-authored a pooled analysis of two placebo-controlled trials in moderate to severe brain injury. The authors concluded the drug was safe and effective and should be considered for guidelines.
Source: Neurological Sciences, 2021
Dafin MuresanuWebsiteRecommends
Photo source: medandlife.org
Wrote that the pig-brain-derived mixture is unproven as a stroke neuroprotectant and that routine use in acute stroke is not justified, citing a Cochrane review that found no effect on death or function.
Matthew FinkWebsiteWarns against
Money: Reports consulting for two large drug companies not linked to Cerebrolysin
Photo source: neurology.weill.cornell.edu
Pooled 7 randomized trials with 1,779 stroke patients. Found no significant gain in disability or daily function scores over placebo and said the evidence did not support routine use.
Danfeng Zhang and colleaguesSourceWarns against
More contextCase reports, watch and read, emerging uses and chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Harm reportedtrial result in rare group - 1773 people - 2023
The 2023 Cochrane review of 7 stroke trials found probably no effect on death. Non-fatal serious adverse events were probably more than twice as common with the drug. Reviewers rated two manufacturer-supported trials at high risk of bias.
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Cerebrolysin
Evidence review: Cerebrolysin is approved in many countries but not the US, looks safe short term, and shows small cognitive gains but weak evidence.
Rare independent evidence summary, though dated 2016
When options run out
Uses people turn to when standard treatment has failed.
Add-on to stroke rehabilitation
- Who
- Patients with moderate to severe ischemic stroke in countries where the drug is licensed.
- Evidence
- The manufacturer reports a 2021 European neurorehabilitation guideline backs early add-on use. The 2023 Cochrane review found no benefit in acute stroke and more non-fatal serious adverse events.
- Route
- Licensed prescription use in parts of Europe and Asia
Source: Manufacturer news page, 2021-07
Moderate to severe traumatic brain injury
- Who
- Hospital patients with brain injury, where few drugs aid recovery.
- Evidence
- Two small placebo-controlled trials pooled to 185 patients showed a small to medium gain on combined functional and cognitive measures at 30 and 90 days, with safety matching placebo. Larger independent trials are lacking.
- Route
- Licensed prescription use in some countries
Source: Neurological Sciences, 2021
Vascular dementia and Alzheimer's disease
- Who
- People with dementia who have exhausted standard drugs, mostly in Europe and Asia.
- Evidence
- A Cochrane review of 6 trials in 597 people with vascular dementia found better cognition and general function scores, but at very low certainty and possibly too small to matter. A charity review found modest Alzheimer's signals not confirmed in large trials.
Long COVID brain fog
- Who
- People with lasting post-COVID cognitive symptoms looking beyond rehabilitation.
- Evidence
- A 2024 systematic review of 17 studies on brain fog treatments in long COVID included no Cerebrolysin study. No controlled evidence was found for this use.
Source: Neurological Sciences, 2024
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
Does Cerebrolysin work for stroke?
A 2023 Cochrane review of seven trials (1,773 people) found no effect on deaths, and no trial reported how many people ended up dead or dependent on others.
Does Cerebrolysin help dementia?
In vascular dementia, a Cochrane review of six trials (597 people) found a small gain in thinking scores that may be too small to matter, with very low certainty. For Alzheimer's disease, the positive pooled results come from small, maker-sponsored trials.
Is Cerebrolysin FDA approved?
No, it was never approved by FDA. There is no EU-wide approval, but it is authorized nationally in some member states, including Austria.
What are the side effects of Cerebrolysin?
Headache, dizziness and agitation. In stroke trials, non-fatal serious adverse events were about twice as common as on placebo, though serious events overall did not differ.
Can Cerebrolysin be taken by mouth?
It is a hospital infusion given into a vein, not a self-injection. Products sold to swallow are broken down in the gut.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Cochrane 2023: Cerebrolysin for acute ischemic stroke
- Cochrane 2019: Cerebrolysin for vascular dementia
- Alzheimer's Drug Discovery Foundation: Cerebrolysin report
Structure: PubChem